节点文献
母子Rh血型不合的孕期治疗
Antenatal Treatment of Maternal-Fetal Rh Incompatibility Hemolysis Disease
【摘要】 目的探讨母子Rh血型不合孕期治疗的新方法。方法对5例重症Rh血型不合孕妇,在孕期除血浆去除外,同时应用静脉滴注丙种免疫球蛋白(IgG)治疗。每次10g,并根据母体抗体滴度,间隔7~20天1次。结果5例孕妇共滴注IgG12次,每例1~5次,平均每例24次,无副作用。血浆去除共18次,每例1~8次,平均每例36次,无一例死胎。5例新生儿经静脉滴注IgG和换血治疗,全部存活。结论IgG可调整胎儿免疫能力,缓解和减轻胎儿溶血的程度
【Abstract】 Objective To study the effective antenatal treatment of maternal-fetal Rh incompatibility hemolysis disease to improve fetal outcome. Methods Besides therapy of plasmapheresis, the immune globulin intravenous infusion (IVIg) was added for antenatal treatment of fetal hemolysis disease due to Rh incompatibility. Every 7~20 days 10 g IVIg was administered according to the titer of Rh antibody in maternal serum. Results 5 Rh negative pregnant women with poor obsterical history were treated with this protocol. Total IVIg infusion was 12 times with an average of 2.4 times per case, and there was no side effects. Plasmapheresis was used 18 times totally with an average of 3.6 per case. There was no fetal death. All the five newborns underwent exchange transfusion and IVIg therapy, and all were survival. Conclusion IVIg may enter fetal blood circulation via placenta, and adjust fetal immune ability to reduce the degree of fetal hemolysis.
【Key words】 Rh-Hr bloodgroup system Erythroblastosis; fetal Immuno globulinns; intrarenous Pregnancy;
- 【文献出处】 中华妇产科杂志 ,Chinese Journal of Obstetrics And Gynecology , 编辑部邮箱 ,1998年07期
- 【分类号】R714
- 【被引频次】23
- 【下载频次】216